Drug Profile
Research programme: protein therapeutics - Ambrx/Pfizer
Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Ambrx; Wyeth
- Developer Ambrx; Pfizer
- Class Antibodies; Drug conjugates; Proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified